Fair Trade Regulator Approves 10.16 Per Cent Stake Buy in Intas by Temasek
New Delhi: The Competition Commission of India (CCI) has cleared Singapore government investment arm Temasek Holding's proposed acquisition of a 10.16 per cent stake in Intas Pharmaceuticals, saying the deal will not raise anti-competition concerns.
Under the proposed deal, Dunearn Investments (Mauritius) Pte Ltd - a indirect subsidiary of Temasek - would acquire the stake from Mozart Ltd - a wholly-owned subsidiary of ChrysCapital III LLC.
In an order released on Monday, the fair trade regulator CCI said "that the proposed combination is not likely to have an appreciable adverse effort on competition in India".
The regulator said that "there are no horizontal overlaps between the products and services of Intas and the rest of the Temasek group".
"...Temasek has some minority investment in the companies engaged in the pharmaceutical and health sector in India including Medreich Ltd, a pharmaceutical company in India," CCI said.
Among others, CCI said that "in respect of the overlapping products of Intas and Medreich Ltd, the combined market share is of minimal nature".
"Further, as stated in the notice neither Temasek nor any of its subsidiaries, associates or joint ventures has any significant vertical linkage with any of the business activities of Intas or its subsidiaries in India," CCI added.
Incorporated in India, Intas is a vertically-integrated pharmaceutical company with global operations.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.
-
Signing Deals Is One Thing; Making Them Work Is Another | The Week In Whys
Sometimes, things don't turn out as planned. Indian companies have lost some bids to rivals, some projects won't produce until 2030.
-
FOMC Wall, PERM Suspension, Hospital Stocks | Talking Points This Week
A PERM suspension would directly affect green-card sponsorship rather than H-1B visas, so the near-term earnings impact could remain relatively limited. The key question is whether this marks a new phase in US scrutiny of Indian IT.
-
Everything, Everywhere, All At Once: Dalal Street's Week To Forget | Joining The Dots
Visa curbs, a Starlink spat and cancer drug caps: what connects this week's shocks for Indian markets
-
India Is Going Abroad For Critical Minerals. But It May Take Years To Pay Off | The Reason Why
Although India's steps are in the right direction, they remain modest compared with India's growing dependence.
